BioSpace News Archive

Santhera Pharmaceuticals publishes preliminary financial results for the half-year ended June 30, 2022.

ANGLE plc, a world-leading liquid biopsy company, is delighted to announce positive headline results from its ovarian cancer clinical verification study, demonstrating that a Parsortix® blood test can be used to determine if a woman is at risk of a malignant pelvic mass.

ANGLE plc, a world leading liquid biopsy company, announces its unaudited interim financial results for the six months ended 30 June 2022.

Hemogenyx Pharmaceuticals plc, the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces its unaudited interim results for the six-month period ended 30 June 2022.

Ultivue, Inc. and, the Translational Research Unit platform of University of Bern announce a collaborative agreement to promote multiplexed immunofluorescence assays and the use of next generation TMAs to unlock spatial analysis in scientific research and improve the quality of TMAs integrated in clinical and translational research.

Myonex, a leading global clinical trial supply company, announces the launch of the first and only on-demand local drug sourcing in Europe.

Cell coding company bit.bio has announced an expansion to its product portfolio - ioGlutamatergic Neurons TDP-43M337V disease model and early access to its ioMicroglia cell product.

NeuShen Therapeutics, Inc. announced the closure of ~$20 million Series pre-A financing led by LAPAM, a China based venture capital.

Galecto, Inc. announced positive results from a planned intermediate assessment of its ongoing Phase 2a trial of GB2064 for the treatment of myelofibrosis.

Spectrum Chemical Mfg. Corp. has entered into a new U.S. distribution agreement with DFE Pharma, a global leader in pharma and nutraceutical excipient solutions.